TOBRADEX ST Rx
Generic Name and Formulations:
Tobramycin 0.3%, dexamethasone 0.05%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for TOBRADEX ST:
Ocular inflammation associated with infection or risk thereof.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop every 2hrs for 1st 24–48 hrs, then every 4–6 hrs. Reduce dose as condition improves; max 20mL for initial ℞.
Viral, fungal, or mycobacterial infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections, intraocular pressure and cataracts in prolonged use. Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Aminoglycoside + steroid.
Local effects (eg, eye pain, eyelids pruritus, eyelid edema, conjunctival hyperemia or erythema), increased intraocular pressure, glaucoma, cataracts, corneal perforations, optic nerve damage, delayed wound healing, secondary infection.
Susp—2.5mL, 5mL, 10mL; Oint—3.5g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma